Findings seen for 1.50 versus 1.25 mmol\/L in patients undergoing hemodialysis<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b>
\n<\/b><\/p>\n
FRIDAY, Oct. 18, 2024 (HealthDay News) — There are no significant differences in all-cause or cardiovascular mortality with the prescription of dialysate calcium 1.50 versus 1.25 mmol\/L for patients undergoing hemodialysis, according to a study published online Oct. 4 in the Clinical Kidney Journal<\/em>.<\/p>\n Karlien J. ter Meulen, from Maastricht University Medical Centre in the Netherlands, and colleagues investigated the association between dialysate calcium and all-cause, cardiovascular, and sudden cardiac death in hemodialysis patients. The analysis included 12,897 patients with dialysate calcium 1.25 mmol\/L and 26,989 patients with dialysate calcium 1.50 mmol\/L initiation.<\/p>\n The researchers found that the unadjusted risk for all-cause mortality was higher for dialysate calcium 1.50 mmol\/L (hazard ratio [HR], 1.07). When fully adjusting for other confounders, there were no significant differences (HR, 1.05; 95 percent confidence interval [CI], 0.99 to 1.12). Similar results were seen for cardiovascular mortality (HR, 1.03; 95 percent CI, 0.94 to 1.13). For sudden cardiac death, risk was lower for dialysate calcium 1.50 mmol\/L (HR, 0.81). With larger serum-to-dialysate calcium gradients, there were significant and positive associations for all outcomes, which were primarily mediated by the serum calcium level.<\/p>\n \u201cThis study supports the European Renal Best Practice recommendations that dialysate calcium prescription should be based on consideration of individual patient characteristics,\u201d the authors wrote.<\/p>\n